Retrospective studies indicate that active surveillance for clinically localized, small renal masses (cT1a, \<=4cm) is safe. It is our hypothesis that active surveillance is safe and efficacious when compared prospectively to patients undergoing immediate intervention for their small renal mass.
Must have a solid, enhancing renal mass ≤4cm at its greatest dimension found on incidental scanning in the last 6 months.
Age ≥ 18 and able to read, understand and sign informed consent.
Must be willing to adhere to the treatment algorithm and time constraints therein.
Cannot have suspicion of metastases to the kidney if any other malignancy diagnosed within two years of study entry.
Abramson Cancer Center at Penn Medicine
Lead sponsor
National Comprehensive Cancer Network
Collaborator